

VSM

1

VSM

FOOD AND DRUG ADMINISTRATION

PUBLIC MEETING ON:

THE CHALLENGE OF LABELING FOOD ALLERGENS

Monday, August 13, 2001

9:05 a.m.

The Cohen Building
Auditorium
330 Independence Avenue, S.W.
Washington, D.C. 20201

ODP-1322

MILLER REPORTING COMPANY, INC.
735 8th Street, S.E.
Washington, D.C. 20003-2802
(202) 546-6666

TRI

C O N T E N T S

	<u>PAGE</u>
Welcome	
Ken Falci, Ph.D. Director, Office of Scientific Analysis and Support	5
Opening Remarks	
Christine Lewis, Ph.D. Director, Office of Nutritional Products, Labeling and Dietary Supplements	9
Congressional Update	
Kate Winkler, Legislative Assistant Office of Nita M. Lowey	20
SOURCE OR PLAIN ENGLISH LABELING	30
Panel I:	
Michael Jacobson, Ph.D. Co-Founder and Executive Director, CSPI	31
Anne Munoz-Furlong President and Founder, FAAN	36
Regina Hildwine Senior Director Food Labeling and Standards Regulatory Affairs, NFPA	41
Lisa Katic, R.D. Director, Scientific and Nutritional Policy GMA	47
Discussion Between Panelists and CFSAN Christine Lewis	52
Felicia Satchell, Director Division of Standards and Labeling Regulations Office of Nutritional Products Labeling and Dietary Supplements	
Ken Falci	
Kathy Gombas, Deputy Director Division of HACCP Programs Office of Field Programs	
Thomas Wilcox, Medical Officer Office of Scientific Analysis and Support	
Questions from the Public	63

C O N T E N T S

	<u>PAGE</u>
ADVISORY LABELING (e.g. "May contain [name of food allergen]")	
Summary of Inspectional Findings FDA/Minnesota and Wisconsin Food Allergen Partnership Theresa Dziuk, Consumer Safety Officer Minnesota District, FDA	73
Panel II:	84
Lisa Katic	84
Regina Hildwine	93
Anne Munoz-Furlong	103
Michael Jacobson	112
Discussion Between Panelists and CFSAN	120
Christine Lewis	
Felicia Satchell	
Ken Falci	
Kathy Gombas	
Thomas Wilcox	
Questions from the Public	132
LABELING OF INGREDIENTS EXEMPTED FROM DECLARATION (Common or unusual names of flavorings, spices and colors; incidental additives)	151
Panel III:	
Michael Jacobson	151
Anne Munoz-Furlong	156
Regina Hildwine	161
John Hallagan, General Counsel FEMA, ASTA and IACM	167
Discussion Between Panelists and CFSAN	172
Christine Lewis	
Felicia Satchell	
Ken Falci	
Kathy Gombas	
Thomas Wilcox	
Questions from the Public	179
Public Comments	187
Closing Remarks	269

P R O C E E D I N G S

1
2 DR. FALCI: I want to say welcome to you
3 all. I know some of you have come a long way and
4 we're all glad you arrived safely. Let me give a
5 special welcome to our panelists. We're very glad
6 you're here today.

7 They've given me a few things to say as
8 far as announcements and sort of housekeeping kind
9 of things. Today is the FDA's Public Meeting on
10 Labeling of Food Allergens, and I'd like to go over
11 some of the administrative details.

12 Everyone should have picked up a packet, a
13 registration packet, at the registration desk. In
14 your packet, you'll see there is a list of
15 restaurants. There is also a cafeteria. There are
16 a lot of restaurants nearby here. There is also a
17 cafeteria in this building downstairs. You have to
18 go down one flight.

19 At the registration desk or a little bit
20 off to the side, you'll be able to see various
21 consumer and industry handouts. We hope you pick
22 up a few of those. The guards, I believe, are
23 requesting those of you that came through the I
24 think this is the Third Street entrance, if you
25 have your visitor's pass on you, that you keep that

1 with you when you enter and leave the building.
2 Use that pass to come back in.

3 If you have any cell phones or beepers,
4 would you just kindly take a look at them now and
5 shut them off.

6 The bathrooms are located in the main hall
7 of this building. When you leave this room, go to
8 the right and you go to the main hallway and
9 they're either on the right or the left-hand side,
10 and if you think about, if you'll think about it,
11 too, on the second floor, it's the same kind of
12 configuration just in case they get a little
13 crowded here on the first floor.

14 We have a sign language interpreter
15 available today. If you know of anyone who needs
16 sign language interpretation, please see the staff
17 people. They'll be walking up and down the aisles.

18 Let's see. One more message for our
19 panelists. The silver microphones are not to be
20 moved. Those are the ones used for recording, and
21 the black microphones are the ones you can move
22 towards you to make any statements you wish.

23 The press has some area here in the front
24 seats; if the press would like to come down and
25 come up front, you certainly may.

1 And let's see, oh, yes, telephones. There
2 are telephones in this building. You can walk out
3 of this auditorium again and go to your right and
4 you'll go past the guard station, and you'll see
5 them right there by the guard station.

6 And I'd like to just do a little summary
7 of where we've come as far as food allergens are
8 concerned. It wasn't very long ago, actually in
9 1999, that FDA first thought about being and
10 becoming more active with food allergens, and we
11 did have discussions and we did formulate a plan of
12 action as far as food allergens were concerned.

13 We formed an internal steering committee
14 within the Center for Food Safety and Applied
15 Nutrition, which is a center in FDA. And we also
16 had a general committee on food allergens made up
17 of a number of people within different offices that
18 are in the Center for Food Safety. And at that
19 time, one of the reasons for our action was because
20 recalls of foods placed in the market, foods that
21 contained undeclared food allergens were at high
22 levels in the nation.

23 And in 2000, we followed that up. We went
24 out with industry, we went out to industry and to
25 consumers. We gathered data at that time. We were

1 seeking advice. We were trying to raise awareness
2 of people in the industry as well as consumers as
3 far as food allergens were concerned.

4 At that time, too, we were trying to
5 decide on accomplishable tasks, those tasks that
6 would make a difference as far as food allergens
7 were concerned in the nation.

8 And in 2001, you see that we have our
9 website established. You can turn to our website
10 and see a variety of different actions that the
11 agency has taken, examples of training as far as
12 our inspectors are concerned, as far as food
13 allergen control measures that are used in
14 processing plants, how the inspector should go into
15 processing plants and look for food allergin
16 processing.

17 There is also a Compliance Policy Guide on
18 our website as well, and we're actively training
19 our inspectors over the next six months or so.

20 Today, we seek further information, and
21 the kinds of things we'll talk about today, you
22 will see eventually in our action plan for fiscal
23 year 2002. So that's what we're trying to
24 accomplish here today as well.

25 On our agenda, there are three subjects.

1 Dr. Christine Lewis, who is the Director of the
2 Office of Nutritional Products and Labeling and
3 Dietary Supplements, will be our moderator today at
4 today's meeting. Dr. Lewis will give you an
5 overview on the issues that we will be discussing
6 here today and mention the agency's regulatory
7 framework. And as your moderator, I'll turn this
8 meeting over then to Dr. Lewis.

9 DR. LEWIS: Thank you, Dr. Falci. And I'd
10 like to add my welcome to his welcome. We are
11 looking forward very much to this meeting, and in
12 our listening mode hope to be gathering a great
13 deal of information today. I will be taking a few
14 minutes to orient us by highlighting the challenges
15 of labeling foods relative to allergens, but as Dr.
16 Falci had some housekeeping rules to say, I have
17 some ground rules to share with you.

18 The purpose of this meeting is to put
19 forward and discuss information to help FDA
20 determine what additional activities we should
21 undertake vis-a-vis the issues surrounding the food
22 label and allergens.

23 So our focus today is labeling. We're not
24 addressing the technical aspects of food
25 processing. More specifically our meeting will

1 address only the topics outlined in the Federal
2 Register Notice, again plain English source
3 labeling, advisory labeling, and labeling of
4 ingredients exempted from declaration.

5 While we recognize there are other issues
6 such as restaurant labeling and even latex glove
7 allergies, these issues are beyond the scope of our
8 discussions today.

9 In terms of ground rules for members of
10 the press here, FDA staff will not be giving any
11 interviews because we are in a listening mode.
12 There are three FDA press officers here today, and
13 they will stand right now. One is Ruth Welch, one
14 is Kathleen Kolar, and Sebastian Cianci. Please
15 see them if you have any questions or need
16 assistance.

17 There will be some brief opportunities to
18 ask written questions to panelists at the end of
19 each panel session. A reminder: these are
20 questions, not comments. And as we move through
21 the presentations, please write your questions on
22 the cards and give them to the ushers as soon as
23 possible.

24 We will get to as many questions as time
25 allows from you folks in the audience. I do need

1 to emphasize the questions from the public should
2 be addressed to the panelists, not to FDA, as again
3 we're in a listening mode.

4 We request that the questions only be on
5 the specific subject that the panel has just
6 discussed.

7 The last part of the meeting will be
8 devoted to public comment. For those of you who
9 wish to make a public comment and have not
10 preregistered, there are sign-up sheets at the
11 registration desk, first come/first served, and
12 these statements should be no longer than three
13 minutes.

14 There will be a timer set up for the
15 public presentations. We'll let you know if you're
16 going beyond your three minutes and need to stop.
17 In addition to the oral public statements at the
18 end of the day, you and anyone else may also submit
19 written comments. They should be sent to Dockets,
20 and again that information is in the Federal
21 Register notice, and if you picked up your package,
22 there is a copy of the Federal Register in your
23 package.

24 There will be a transcript of the meeting
25 available approximately one month after the

1 meeting. The transcript will be available at FDA's
2 website, again in your package, www.cfsan.fda.gov.

3 Before I turn to highlighting our
4 challenges today, I'd like to introduce our
5 panelists. In no particular order, we have sitting
6 with us today Regina Hildwine, who is Senior
7 Director, Food Labeling and Standards, Regulatory
8 Affairs at the National Food Processors
9 Association.

10 We have Dr. Michael Jacobson, Co-Founder
11 and Executive Director of the Center for Science in
12 the Public Interest.

13 With us also is Lisa Katic, Registered
14 Dietician, and Director, Scientific and Nutrition
15 Policy at the Grocery Manufacturers of America.

16 And also Anne Munoz-Furlong, President and
17 Founder of the Food Allergy and Anaphylaxis
18 Network.

19 We also will have with us John Hallagan,
20 who is General Counsel of the Flavor and Extract
21 Manufacturers Association, American Spice Trade
22 Association, and also with the International
23 Association of Color Manufacturers, who will
24 participate on Panel III this afternoon.

25 We also will have with us Kate Winkler,

1 Legislative Assistant from the office of the
2 Honorable Nita M. Lowey, who will give an update on
3 congressional activities related to the labeling of
4 food allergens. Ms. Lowey's office was invited
5 today because she's initiated draft legislation on
6 the labeling of food allergens.

7 I appropriately need to inform you at this
8 point that the current administration has not taken
9 a position on such labeling.

10 And finally, I'd like to introduce the FDA
11 listening panel, which is directly on my left.
12 First there is Dr. Ken Falci, from whom you've
13 already heard.

14 We also have Felicia Satchell, who is
15 Director of the Division of Standards and Labeling
16 Regulations in the Office of Nutritional Products,
17 Labeling and Dietary Supplements.

18 We have Kathy Gombas, who is Deputy
19 Director of the Division of HACCP in the Office of
20 Field Programs.

21 And Thomas Wilcox, who is a Medical
22 Officer within the Office of Scientific Analysis
23 and Support.

24 And finally, Theresa Dziuk, Consumer
25 Safety Officer, FDA's Minneapolis District Office,

1 who will discuss the summary of inspectional
2 findings from the FDA/Minnesota and Wisconsin Food
3 Allergen Partnership.

4 So, at this point, I will take just a few
5 minutes with the slides to highlight the challenges
6 that we're facing relative to labeling of food
7 allergens.

8 I believe I can do this; correct? There
9 we go. Keep going. Technology will help us some
10 day. We're just not there yet.

11 As I've already mentioned, the focus of
12 the meeting today is threefold: source or plain
13 English labeling; advisory labeling; and labeling
14 of ingredients exempted from declaration.

15 And more specifically, our meeting will
16 focus on the eight most common allergens listed
17 here: peanuts, soy, milk, eggs, fish, crustacea,
18 tree nuts and wheat.

19 Next. As a bit of background, our current
20 regulatory framework is such that the labels of
21 food made from two or more ingredients list each
22 ingredient by its common or usual name in
23 descending order of predominance by weight in the
24 ingredient statement.

25 Thus, consumers can obtain information

1 about the foods that they eat by reading the
2 ingredient list. There are, however, two
3 exceptions.

4 The first is that the act provides that
5 spices, flavorings and colorings may be declared
6 collectively without naming each.

7 Second, FDA regulations exempt from
8 ingredient declaration incidental additives such as
9 processing aids that are present in a food at
10 insignificant levels and that do not have a
11 technical or functional effect on the finished
12 food.

13 However, I need to point out that FDA's
14 policy is that an allergenic ingredient is not
15 insignificant and therefore is not exempt from
16 labeling.

17 In terms of the current state of play, FDA
18 has two petitions in-house regarding food
19 allergens. One is from the Attorneys General from
20 nine states and requests FDA require a variety of
21 activities including allergen information on the
22 label, an insignia, toll free telephone numbers,
23 good manufacturing practices, and labeling of
24 flavors and incidental additives.

25 The second is a petition from a consumer

1 addressing very similar issues.

2 Next. We also are aware of NFPA's Code of
3 Practice on Managing Food Allergens. This code of
4 practice is a voluntary program adopted by NFPA's
5 members.

6 Most recently, we've received and are
7 aware of guidelines from the Food Allergy Issues
8 Alliance. The Food Allergy Issues Alliance is a
9 private group comprised of industry and trade group
10 representatives and a consumer group as well as a
11 scientific advisor representing academia. In May,
12 they submitted to us a consensus document on
13 guidelines for food allergen labeling.

14 The questions on which FDA is seeking
15 information are spelled out in detail in the
16 Federal Register. So just very briefly, they are,
17 first, questions on source labeling. We're asking
18 what plain English terms would be understandable.
19 That is terms such as "milk" instead of "whey."
20 And we're asking about what formats would be most
21 informative. The issues are things such as formats
22 in the ingredient statement itself versus below the
23 ingredient statement as one example.

24 Also, in terms of source labeling--next
25 slide--we're asking about whether or not multiple

1 formats would be confusing and should source
2 labeling be voluntary or mandatory?

3 Second, we have a set of questions on
4 so-called advisory labeling, advisory labeling
5 falling into the category of such things about "may
6 contain" and its impact on consumers.

7 And, in the next slide, questions about
8 the appropriateness of advisory labeling including
9 questions should the recommendations in the State
10 Attorneys General petition be adopted and what
11 about the criteria in the Food Allergy Issues
12 Alliance?

13 Next slide. In terms of advisory
14 labeling, we're also asking are there better
15 alternatives to advisory label statements and do
16 advisory statements adequately inform consumers? I
17 should add that examples of current advisory labels
18 in practice include, for instance, "may contain
19 peanuts" or "manufactured in a facility that also
20 processes peanuts."

21 Next slide. We are also asking should
22 these advisory statements be prescriptive and what
23 should be the location and prominence of these
24 statements?

25 The third set of questions focuses on

1 flavorings, spices and colors. We're asking if FDA
2 should continue to address the labeling of
3 individual allergenic flavors, spices and colors on
4 a case by case basis. We also raise the question
5 of label location and the issue of mandatory versus
6 voluntary labeling.

7 And in the next slide, we've also asked
8 for comments on the labeling of incidental
9 additives. What minor ingredients or processes
10 would manufacturers be unlikely to recognize? And
11 also when products are to be further processed or
12 repacked, is better labeling on intermediate
13 products necessary?

14 The questions on the labeling of
15 incidental additives in terms of lastly, we're
16 asking whether FDA should codify its policy that
17 allergens cannot qualify as incidental additives
18 that are exempt from labeling?

19 That basically highlights the purpose and
20 issues we'd like addressed today during our
21 meeting, and at this point, I think we will
22 actually begin our program.

23 More or less without further ado, we'd
24 like to turn to some remarks from Ms. Kate Winkler,
25 who as we've mentioned before is from the Office of

1 Congressman Lowey. Ms. Winkler.

2 MS. WINKLER: Good morning. I'm delighted
3 to be here today. It's also a pleasure to see so
4 many people here that the Lowey office has worked
5 so closely with. I too have to do a little good
6 housekeeping before we start and say that I am Mrs.
7 Lowey's legislative assistant. I handle her food
8 safety and agricultural work. However, I'm not an
9 official spokesperson for the congresswoman. If
10 the press has any questions for the Lowey office,
11 you can feel free to give us a call afterwards and
12 speak with our press person. I'm just not at
13 liberty to do so.

14 I'm here in my legislative capacity to
15 talk about the work that my boss has been doing
16 over the last year and a half on the food allergin
17 issue and let you know where our piece of
18 legislation stands at this point. Mrs. Lowey has a
19 long record of achievement on food safety issues.
20 She wishes she could be here today. She's actually
21 up in New York catching up on a little district
22 time, but Mrs. Lowey was formerly on the
23 Agriculture Appropriations Subcommittee.

24 On that subcommittee, she took a strong
25 interest in food safety issues. She's introduced

1 legislation that would require manufacturers to put
2 a "best if used by" date on all perishable foods.
3 She's also authored legislation that would require
4 all fresh meat and poultry products to come with a
5 nutrition label just as prepackaged food does, but
6 her interest in the food allergy issue has taken
7 her pro-consumer work to a new level.

8 I'd say about two years ago, we started to
9 receive a number of mail and, you know, when she'd
10 be in the grocery store making shopping visits--you
11 know she's been a member of Congress now for more
12 than ten years--people would come up to her and let
13 her know their frustration with reading labels, and
14 that's when she turned to me and said what can we
15 do about those that have a food allergy and can't
16 get the information that they need off of a food
17 label?

18 So, you know, unfortunately, misleading
19 and insufficient labels are not only a burden for
20 some of us who look for expiration dates, but it's
21 a serious health hazard for the millions of
22 Americans with a food allergy. Food allergic
23 consumers and the parents of food allergic children
24 do not have a choice. Their health and lives
25 depend on reading labels.

1 That's why Mrs. Lowey moved to introduce
2 the Food Allergen Consumer Protection Act. An
3 estimated 30,000 Americans suffer severe and even
4 life-threatening reaction to foods each year and
5 about 150 of them die. While we can't prevent
6 allergic reactions, we can enact common sense food
7 labeling requirements that will help consumers
8 avoid allergen laced foods.

9 Currently, even those with a food allergy,
10 even if they read labels for every food product
11 they purchase every time they shop, they still
12 cannot be assured that a product is safe.

13 For example, under current regulations,
14 food manufacturers do not have to identify the
15 products used in certain flavorings or additives.
16 This exemption leaves critical health and safety
17 information off our food labels. Although
18 flavorings and additives are present in small
19 quantities, for the millions with a food allergy no
20 amount is irrelevant.

21 Furthermore, ingredient statements are
22 written for scientists, not consumers. For
23 example, how many people know that surimi is
24 another term for egg. Food allergic children
25 should not be expected to decipher terms like

1 "casein, albumin, or muso."

2 The bill that my boss has sponsored would
3 require that food statements list in plain language
4 what if any of the eight food allergens are
5 contained in a product.

6 Beyond improving the readability of
7 labels, it's time for manufacturers to clean up
8 their acts. Too many manufacturers are preparing
9 multiple products with the same cooking utensils or
10 on the same production lines without properly
11 cleaning the equipment. These practices must stop.
12 A recent FDA study found that one-quarter of all
13 manufacturers did not list ingredients that can
14 cause potentially fatal allergic reactions and 47
15 percent of manufacturers did not check their
16 products to ensure that all ingredients were
17 accurately portrayed on the label.

18 There is no excuse when it comes to health
19 and well-being of our children. Manufacturers
20 should be taking every step possible to ensure
21 their product safety. And as mentioned, the
22 industry did recently propose voluntary guidelines,
23 and my boss has worked very, very well with
24 organizations like Grocery Manufacturers and
25 National Food Processors Association, and she was

1 incredibly pleased that these guidelines were
2 issued a couple months ago, and she has applauded
3 the industry for taking to heart the seriousness of
4 this health hazard.

5 But the fact is these are voluntary
6 guidelines. The legislation will give some of the
7 suggestions the weight of statutory law and ensure
8 that every manufacturer abide by some of the
9 suggestions made in the guidelines. Furthermore,
10 it will provide the Food and Drug Administration
11 with the resources to enforce the law.

12 As I said earlier, before we introduced
13 the bill in the last Congress, and I should say
14 that the bill introduced in the 106th Congress is
15 very, very different than the one we'll be
16 introducing in the 107th Congress. But before we
17 introduced that bill, companies like Kraft and
18 General Mills were already imposing stricter
19 labeling standards, and we did use their labels as
20 a model to work off of.

21 In addition, we enlisted the help of NFPA
22 and GMA to help us raise awareness of the problem
23 in the industry, and I think their guidelines show
24 that they really have taken to heart some of the
25 work that my boss has done and others.

1 To go point for point exactly what our
2 bill does is again it requires that food ingredient
3 statements identify in common language what if any
4 of the eight main allergens are in a product. It
5 closes the food additive loophole which requires
6 that on the ingredient statements if an allergen is
7 used in any of the spices or natural or artificial
8 flavorings that it be labeled as such.

9 It preserves the Food and Drug
10 Administration's authority to regulate the safety
11 of certain bio-engineered products. It requires
12 food manufacturers to include a working telephone
13 number, including one for deaf persons in case a
14 family has an emergency and they'd like to contact
15 the actual manufacturer themselves to have
16 questions answered.

17 It requires food manufacturers to better
18 prevent cross-contact between food products that
19 are produced in the same facility or on the same
20 production line. It also would disallow the use of
21 "may contain" language except for those that the
22 Food and Drug Administration would allow. So that
23 would put the FDA in charge of deciding in what
24 instances a "may contain" language label is
25 appropriate.

1 It would allow the Food and Drug
2 Administration to assess civil penalties against
3 processes and plants that are in violation of the
4 labeling manufacturing requirements for food
5 allergens. Furthermore, it would require the
6 Center for Disease Control to attract food allergic
7 related deaths. Fortunately, we don't have
8 reliable and accurate statistics right now.

9 And lastly, it would direct the NIH,
10 National Institutes of Health, to convene a panel
11 of experts to develop a plan for research
12 activities concerning food allergens. So that's
13 the bill in sum.

14 In closing, I'd like to say that the bill
15 will probably be introduced just after August
16 recess. The bill will be introduced in both
17 chambers. Part of the hold-up has been we've been
18 working with Senator Kennedy on creating a bill
19 that is suitable for both chambers so that we can
20 have the same bill introduced on both sides of the
21 Hill.

22 We've also been trying to educate other
23 offices about the bill, let them know what we're
24 looking to achieve, and in doing so, we've held a
25 briefing where we had Dr. Sampson, one of the

1 leading doctors on food allergens, from Mount Sinai
2 come down to the Hill and brief staff.

3 We've also been working very closely with
4 some organizations like Food Allergy Initiative,
5 FAAN and CSPI, and let them activate their base so
6 that like the constituents who reached out to my
7 boss to say that this is something that is needed,
8 we need to have accurate, reliable, readable
9 labels, that they can let their members of Congress
10 know that this is important to them, and that they
11 should get on board with Mrs. Lowey, Senator
12 Kennedy, and cosponsor our legislation.

13 The only way this legislation is going to
14 move is if we show that we have bicameral,
15 bipartisan support, and I believe we do. But the
16 only way that message is going to be made clear is
17 if people contact their members and let them know.
18 So it's very important that some of the groups here
19 today, some of the families and children that are
20 here today, get in touch with their members of
21 Congress and let them know what's important to them
22 and how a labeling law like this could make their
23 daily lives easier.

24 I'd also like you to know that earlier
25 this year the House passed the agriculture

1 appropriations bill and in that bill was report
2 language that asked the Food and Drug
3 Administration to act on the Attorney General
4 petition that put forward to them suggestions on
5 how to make labels more readable and how to address
6 some of the concerns for food allergic families and
7 their children.

8 In closing, I'd like to say I'm so pleased
9 that FDA is having this public forum, as is Mrs.
10 Lowey. I think this is a step in the right
11 direction. I also think we need to get moving now.
12 The voluntary guidelines were a huge, huge first
13 step, but we need to ensure that every product on
14 our shelves is readable, accurate and reliable so
15 that families can feel confident about the food on
16 their tables.

17 Thank you.

18 [Applause.]

19 DR. LEWIS: Thank you, Ms. Winkler. We'll
20 now turn to our first panel today which addresses
21 the source or plain English labeling. We have with
22 us four panelists who will each make brief five
23 minute comments on this topic, which will be
24 followed by a discussion among the panelists
25 themselves with input from our own FDA listening

1 panel.

2 We'll begin with Dr. Michael Jacobson,
3 followed by Ms. Anne Munoz-Furlong, Ms. Regina
4 Hildwine, and then Ms. Lisa Katic. Dr. Jacobson.

5 DR. JACOBSON: Thank you very much, Dr.
6 Lewis, and I must say that I really appreciate the
7 FDA holding this important meeting, the first one I
8 can recall on food allergies. I think it indicates
9 that the FDA is taking this issue very seriously.

10 Ingredient statements on food labels
11 should be printed in a readable typeface and should
12 clarify which ingredients might cause allergic
13 reactions. Unfortunately, all too many ingredient
14 lists are unreadable due to the small size and
15 style of typeface used. Consumers shouldn't have
16 to play the game of "Where's Waldo" when they're
17 shopping to find the ingredients they're concerned
18 about.

19 I have two examples here of some basically
20 unreadable ingredient lists. The first one is a
21 Stovetop Oven classic pasta--I guess it's pasta; I
22 don't know what it is--for your inspection. And
23 another one is a Hormel Kid's Kitchen product--the
24 next slide, please--that really challenges people
25 to read ingredients.

1 Labels such as these make a mockery of the
2 FDA's requirement that ingredient lists shall
3 appear prominently and conspicuously. Also,
4 ingredient labels typically give the chemical names
5 of additives such as sodium caseinate, lactose,
6 albumen or gluten. That's enough of that slide,
7 please.

8 This Quaker product, for instance,
9 includes whey and sodium caseinate without
10 disclosing that they are milk derivatives.

11 It can be tough for the average person to
12 memorize all the possible derivatives of foods to
13 which they're allergic. To help people who are
14 sensitive to the eight major allergens and the raft
15 of less common but sometimes no less severe
16 allergens as well as for consumers who use
17 ingredient lists for other purposes, the FDA should
18 require all products to bear an entirely redesigned
19 ingredients level which is on the poster in front
20 of you.

21 Last month, CSPI formally petitioned the
22 FDA to provide an ingredient facts label that is
23 consistent with the nutrition facts label. The
24 ingredients label should be printed in clearer
25 larger type using upper and lower case letters,

1 major and minor ingredients should be separated
2 out, and a clear allergy information section should
3 alert sensitive consumers.

4 That section would include such statements
5 as contains milk, soy and wheat or may contain
6 peanuts. This particular label was designed by the
7 same firm, Greenfield-Belser, that designed the
8 nutrition facts label for the FDA about ten years
9 ago. The wording and location of such information
10 should be as standardized as possible on all
11 packages.

12 It has been suggested that the sources of
13 various food additives such as whey and albumen be
14 declared after the names of the additives in the
15 ingredient lists. So labels would state "whey (a
16 milk derivative). "

17 If a clear ingredient facts label with an
18 allergy information section is adopted, I'm not
19 sure whether that redundancy is needed, whether the
20 sources of the major allergens need to be stated in
21 the ingredient list.

22 Focus groups could explore that matter and
23 the request by the attorneys general that an "A" in
24 a circle be printed on the front label to alert
25 consumers about the presence of allergens.

1 While the FDA has focused on the eight
2 most common allergens, I urge you to at least add
3 sulfites to that list. Sulfites are not allergens
4 but still cause life threatening anaphylactic
5 reactions and must be listed on labels when present
6 at 10 ppm, ten parts per million, or more.

7 Finally, the FDA should prevent consumer
8 confusion about products that claim to be non-dairy
9 or wheat-free or vegetarian when they actually
10 contain additives from derived from milk, wheat or
11 animals.

12 The front label of this product, for
13 instance, says "vegetarian and soy cheese," but the
14 manufacturer told us that the natural flavoring is
15 actually skim milk, and the ingredient listed
16 discloses calcium caseinate, both of which
17 ingredients people with milk allergies and strict
18 vegetarians would avoid. That kind of misleading
19 labeling should simply not be allowed.

20 In sum, people with allergies and the rest
21 of consumers need a clear legible ingredient fact
22 statement with an allergy information section.
23 That would do wonders to help people avoid the
24 major allergens as well as other ingredients about
25 which they're concerned. Thank you very much.

1 [Applause.]

2 DR. LEWIS: Thank you, Dr. Jacobson.
3 Before we turn to Ms. Anne Munoz-Furlong, I'd like
4 to remind the audience that you do have the
5 opportunity to write questions on cards. We have
6 several ushers who will be walking among you to
7 pick these up. So as questions arise, please feel
8 free to write them on the cards.

9 Go ahead, please.

10 MS. MUNOZ-FURLONG: Thank you. I have
11 some slides. Shall I ask you to change them or do
12 I--okay--fine. As we bring up these slides, I want
13 to make the point that FAAN is a nonprofit
14 organization. Our mission is to increase
15 awareness, provide education and advance research
16 into the conditions under which reactions and
17 fatalities occur. We have 23,000 members. Most of
18 these are parents of children with food allergies.
19 Can we flip the slide and go on to the next one?

20 My objectives this morning--you can flip
21 to the next one--thank you--are to give you
22 information about the size of this problem, who is
23 affected, and what the confusion is with the
24 current labels. Next slide, please.

25 Currently, food allergies affect about

1 seven million Americans. About three million
2 Americans are allergic to peanuts and tree nuts,
3 and study after study continues to show that
4 peanuts and tree nuts are the leading cause of
5 severe or fatal reactions in this country.

6 Children are the largest group affected by
7 food allergy. Up to six percent of children have a
8 food allergy and eight foods account for 90 percent
9 of the allergic reactions.

10 Next slide, please. Now, we know this
11 list. The point I want to make here is that almost
12 all of these foods have caused a fatal reaction to
13 a child or an adult in this country.

14 Next slide. There is no cure for food
15 allergies. Strict avoidance is the only way to
16 avoid a reaction. That means the individuals must
17 read the label for every product every time they go
18 to the store.

19 Next slide. Food allergy is the leading
20 cause of anaphylaxis. This is a larger problem
21 than insect sting and medication allergy combined.
22 There are about 30,000 emergency room visits a year
23 and tens of thousands of reactions that are taken
24 care of at home. Additionally, about 150 to 200
25 people die from these reactions.

1 Next slide. Okay. This is it. The
2 symptoms can occur within minutes, and in every
3 case the individual is eating something they
4 believe is safe. So we're not talking about risk
5 takers.

6 Next slide. Now let's talk about the
7 confusion with the current labels. The first stop
8 is when we go to the doctor and get a diagnosis,
9 the doctor makes a diagnosis and tells the patient
10 go home and avoid milk or eggs or wheat. They
11 don't know that they're not going to see those
12 names on very many products until they get to the
13 grocery store.

14 If I could have the next slide, please.
15 Now, this is just a sampling of what we call milk
16 words. When someone has a milk allergy, they need
17 to learn casein, caseinates, lactalbumin. These
18 are the types of terms that they need to become
19 familiar with, yet they're looking for the word
20 "milk."

21 Then there is a whole host of situations
22 under which the product may contain milk depending
23 on the product, and that will change. They need to
24 learn this as well.

25 Next slide. When we look at eggs, you can

1 see that some of these terms are very scientific
2 and they certainly aren't consumer friendly.

3 Next slide. When we look at wheat, again
4 the individual is going to the store expecting to
5 see "wheat," but they're going to have to learn
6 that semolina and durum and some of these other
7 terms are what they need to avoid.

8 Next slide. Now, we have conferences
9 across the country. Last year, there were 760
10 attendees. We conducted a survey looking at
11 labeling and had 550 respondents.

12 Next slide. We asked them when they see a
13 label, do they consider that the food labels
14 currently on the market are easy to understand? 88
15 percent disagreed. 98 percent told us that the
16 information on the label is not enough regarding
17 allergens. 99 percent disagreed with the statement
18 that the current labels can be understood by a
19 seven year old. A seven year old would be about
20 the first age that you can expect a child to start
21 to learn to look for milk or eggs or some of the
22 words that they're allergic to.

23 And 98 percent told us that the current
24 labels are not easy to be understood by a new
25 babysitter, a teacher, scout leader, anyone else

1 who is giving information or food to a child.

2 Now, the top three concerns--this was a
3 write-in section to the survey--were "may contain,"
4 natural or artificial flavoring, and non-dairy. I
5 know we have other panels to discuss "may contain"
6 and non-dairy so I'm not going to stop here. The
7 "non-dairy" bears mentioning for another discussion
8 at a future meeting. This is certainly a big issue
9 for our families.

10 Next slide. So when we're talking about
11 labels, there is no cure for food allergy. Strict
12 avoidance is the only way these people can avoid a
13 reaction. Therefore, the labels must be clear and
14 easy to understand. They must be consistent and
15 reliable.

16 And the next slide. We recommend that
17 these labels state in simple English terms adjacent
18 to the ingredient panel what that product contains;
19 that the allergens be identified when they're in
20 these products at all times; and that there be a
21 phone number so that the individual can contact the
22 manufacturer whenever they have a question and
23 we'll talk more about that as we go forward.

24 I want to sum up with one of the comments
25 from our members is that we are not food

1 scientists, we're just mom and dad. Thank you.

2 [Applause.]

3 DR. LEWIS: Thank you. Regina Hildwine.

4 MS. HILDWINE: NFPA thanks FDA for the
5 opportunity to participate in these panels today,
6 and we will also be filing written comments. The
7 National Food Processors Association is the voice
8 of the \$460 billion food processing industry on
9 scientific and public policy issues involving food
10 safety, nutrition, technical and regulatory matters
11 and consumer affairs.

12 My remarks today are all based on the Food
13 Allergen Labeling Guidelines issued by the food
14 allergy issues alliance. NFPA is a member of the
15 Food Allergy Issues Alliance, and NFPA members
16 support the Food Allergen Labeling Guidelines.
17 NFPA believes that it is important to present
18 information on the major food allergens in terms
19 commonly understood by consumers. NFPA believes
20 that plain language presentation options should not
21 replace but should rather augment current
22 ingredient labeling requirements.

23 NFPA also believes that the approaches
24 outlined in the Food Allergen Labeling Guidelines
25 are sufficiently flexible to suit various

1 situations and serve as a useful start for this
2 discussion.

3 NFPA believes that plain language labeling
4 options should be voluntary. To require such
5 declaration would necessitate rulemaking on several
6 standards of identify and other existing rules, and
7 this is an unnecessary complication.

8 Food allergen information presented in
9 plain language terms will help food allergic
10 consumers including children and other challenged
11 readers to recognize the foods they must avoid.
12 Plain language labeling also makes it easier for
13 the caregivers of food allergic children to
14 recognize the food allergens to which their charges
15 are sensitive.

16 The major food allergens as defined by FDA
17 are not all single foods. Crustaceans, fish and
18 tree nuts represent classes of foods. Within these
19 classes of foods, food allergen information must be
20 presented as the common or usual name of the
21 individual food in the ingredient declaration.

22 For example, for crustaceans, crab,
23 crayfish, lobster and shrimp are the terms that
24 would be used. For fish, the common or usual name
25 of the fish species must be declared in the

1 ingredient list. Likewise, for tree nuts, the
2 individual types of allergenic nuts must be
3 declared.

4 Other foods that contain allergenic
5 proteins should include the plain language name of
6 the allergen. In many cases, the plain language
7 name of the allergen is used within the ingredient
8 declaration as the common or usual name of the food
9 ingredient or its standardized name.

10 For example, hydrolyzed soy protein,
11 buttermilk, peanut butter, cracked wheat and milk
12 chocolate all include the plain language names of
13 major food allergens as part of their common or
14 usual names or standardized names. In these
15 instances, food processors declare the plain
16 language names of food allergens through ingredient
17 declaration.

18 When the plain language name of the
19 allergen is not declared in the ingredient list,
20 food processors should ensure that plain language
21 terminology is present in association with the
22 ingredient list.

23 Now, standards of identity can complicate
24 the issue of declaring plain language names for
25 food allergens, but these complications can be

1 resolved.

2 For example, the standardized food egg
3 albumin specifies egg, and that's required in the
4 standard. Dried yolks, a name permitted by that
5 standard, should be supplemented with the term
6 "egg." The ingredient would be dried egg yolks, a
7 name permitted by the standard, which could be
8 declared on the ingredient list as egg yolks.

9 Now, despite what you heard earlier, you
10 would not see the word "surimi" to represent egg.
11 Surimi is derived from fish and on the ingredient
12 list of a surimi product, you are likely to see the
13 term "fish protein."

14 With respect to wheat, semolina, farina,
15 durum flour, graham flour, and white flour, all
16 standardized names, should include the term "wheat"
17 and the dozens of standardized cheeses all declare
18 "milk" as a sub-listed ingredient.

19 Plain language terms for the major food
20 allergens should appear within, at the end of, or
21 in immediate proximity to the ingredient
22 declaration. One option is to place at the end of
23 the ingredient declaration a statement such as
24 "contains peanuts." It could be prefixed by a
25 phrase that highlights attention of the food

1 allergic consumers such "allergy information:
2 preceding contains peanuts."

3 The same effect could be accomplished with
4 the use of a reference mark, such as an asterisk
5 next to the name of the ingredient whose common or
6 usual name does not include the plain name of the
7 allergen, such as farina or casein, each followed
8 with a reference mark. That would then refer to a
9 corresponding notation at the end of the ingredient
10 list that would say "wheat" or "milk ingredient."
11 This option takes up very little space and could be
12 useful for long ingredient declarations.

13 Another alternative is to use within the
14 ingredient declaration a parenthetical statement
15 that follows the ingredient name such as "farina
16 (wheat)." Any of these options, "contains,"
17 reference mark, parentheses, could use bold in
18 their other highlighting to feature the information
19 about food allergens.

20 NFPA does not believe that multiple format
21 options should be confusing to consumers provided
22 the food allergen information is always presented
23 in association with the ingredient declaration.
24 This is where food allergic consumers are
25 instructed to look for information about the

1 allergens in food.

2 Finally, plain language labeling for food
3 allergens should be permitted on a voluntary basis.
4 A mandatory approach would necessitate FDA revising
5 a number of rules for standards of identity and
6 other labeling rules. This would complicate a
7 labeling approach that can be done, and it is now
8 being done on a voluntary basis. Thank you very
9 much.

10 [Applause.]

11 MS. KATIC: Good morning. My name is Lisa
12 Katic and I am the Director of Scientific and
13 Nutrition Policy for the Grocery Manufacturers of
14 America. GMA is the world's largest association of
15 food, beverage and consumer products and works at
16 the federal, state and local level on regulatory
17 and scientific issues.

18 GMA member companies are committed to
19 meeting the needs of the food allergic community.
20 And I'd like to commend FDA for holding this public
21 meeting to collect information on this very
22 important issue.

23 GMA along with numerous trade associations
24 formed the Allergy Issues Alliance several years
25 ago because the food industry wanted to be

1 proactively out front of and address this allergy
2 issue.

3 The Food Allergy and Anaphylaxis Network
4 is an integral part of the Allergy Issues Alliance
5 and as the association that represents food
6 allergic consumers, FAAN is best positioned to
7 provide insight into the labeling practices that
8 would be of most use to the subset of the
9 population. We really appreciated their input and
10 work in developing our guidelines.

11 As Regina has already mentioned, the
12 voluntary program has been developed by the
13 Alliance and was released this spring. It's a
14 culmination of several months of work by the
15 Alliance including FAAN and some other, as was
16 mentioned earlier, food allergy scientific experts.
17 Unlike a regulatory process that will take several
18 years to develop and implement, the Alliance's
19 voluntary program is now in the implementation
20 stage.

21 GMA's Board of Directors has adopted the
22 Alliance's labeling programs and the CEOs of each
23 of our member companies have asked their companies
24 to implement the program. We fully expect
25 widespread adoption and implementation of our

1 labeling programs by our companies in the very near
2 future and as was already mentioned, some companies
3 have been actively making changes since the
4 adoption of this program.

5 With regard to the plain English labeling,
6 the Alliance's labeling program specifically
7 addresses this issue and requires the use of plain
8 English names on the label of foods that contain an
9 allergenic protein that is derived from one of the
10 major allergens.

11 We recognize that it can be daunting for
12 the food allergic consumer to learn the names of
13 all of the ingredients that may be derived from an
14 allergin. Milk is a classic example. As Anne
15 showed earlier, there are numerous ingredients
16 derived from milk.

17 In accordance with FDA's regulations, each
18 of these milk-derived ingredients must be declared
19 in the ingredient statement by a different name.
20 Casein, sodium caseinate and whey are just a few
21 examples of the milk-derived ingredients that must
22 be avoided by a consumer with a milk allergy.

23 The Alliance's labeling program makes it
24 easier for the milk allergic consumer to identify
25 products that he or she needs to avoid by requiring

1 the use of the common term "milk" in addition to
2 the name of the ingredient on the label of foods
3 that contain an allergenic protein from milk.

4 As the agency is well aware, we have a
5 tremendously diverse food supply that uses a wide
6 variety of ingredients. Packaging materials are
7 different as well as packaging sizes. Given this
8 variety, there must be flexibility in presenting
9 the common names of the allergens. The Alliance's
10 labeling program provides this flexibility by
11 offering options for presenting the major
12 allergen's common name.

13 For example, a manufacturer could use
14 parenthetical statements that identify the plain
15 English name of the allergen in the ingredient
16 statement after the ingredient. An allergen
17 information statement could also be highlighted or
18 used in the ingredient declaration panel and then
19 it would list the common name of each of the major
20 allergens in the food.

21 The Alliance's program provides other
22 means of presenting the name of the common allergen
23 as I think Regina has already laid out. The plain
24 English name would appear either in the ingredient
25 statement or in immediate proximity to the

1 ingredient statement.

2 In summary, we support the use of common
3 and plain English names on labels of foods that
4 contain major allergens, and we believe that the
5 Alliance's labeling program sufficiently addresses
6 how this information should be presented.

7 Because we anticipate widespread adoption
8 of this program by the food industry, we believe
9 that the allergen-labeling regulations are
10 unnecessary. Thank you.

11 [Applause.]

12 DR. LEWIS: Thank you very much to members
13 of our panel, and as scheduled on the agenda, we
14 will now begin a 15 minute discussion among members
15 of the panel as well as with the FDA listening
16 panel. Let me remind you that that will be
17 followed by the opportunity for us to address the
18 questions you may be writing down on your cards,
19 and again there are people walking the aisles so
20 please do take advantage of that.

21 Relative to source or plain English
22 labeling, are there particular issues anyone among
23 our panelists would like to address? Dr. Jacobson.

24 DR. JACOBSON: I'd just like to ask Lisa
25 how you could rely upon that voluntary flexible

1 labeling when there are thousands of food producers
2 that are not members of NFPA and GMA? Many
3 companies have never heard of these trade
4 associations and things can change from one
5 management to another management. I think the
6 consumer needs to be assured that the clear
7 English, the labeling will always be there.

8 MS. KATIC: Well, no doubt I appreciate
9 that as a definite challenge. I would say that
10 NFPA and GMA members represent a majority of food
11 products on the shelves. So certainly we have the
12 bulk of what we're talking about covered within our
13 membership.

14 We've talked about--through Alliance
15 outreach we certainly plan on doing a lot of
16 education amongst our own industry, our own
17 industry reaching out to other smaller
18 manufacturers that potentially are not amongst our
19 membership. We've got some discussions already
20 underway on how to do that as well as educating.
21 You know we have lots of large and small and
22 medium-sized companies within our own memberships
23 and we think that it's imperative that some of the
24 larger manufacturers that have long-term experience
25 with how to make changes on labels would be best

1 served by educating some of our medium and smaller
2 sized companies. So it's really all about
3 education and outreach and we have plans underway
4 to do that.

5 DR. LEWIS: Other questions? Kathy
6 Gombas.

7 MS. GOMBAS: Yes. This is Kathy Gombas
8 with FDA. I'd like to ask a question of NFPA,
9 Regina. You had indicated that source or plain
10 English labeling should be voluntary versus
11 mandatory because there are a lot of manufacturers
12 currently using voluntary labeling. Do you have a
13 prospective on how many manufacturers are doing
14 this today?

15 MS. HILDWINE: I can tell you that at the
16 present time, the Food Allergy Issues Alliance, and
17 NFPA, of course, is a member of the Food Allergy
18 Issues Alliance, is developing a survey so that we
19 can collect some baseline data from the food
20 industry regarding their awareness of the Food
21 Allergen Labeling Guidelines and their use of
22 various presentation techniques. We expect to
23 field this survey, you know, the individual
24 associations in the Alliance to our various members
25 probably in the next month or so.

1 Now, there are many more food trade
2 associations besides NFPA and GMA and the Food
3 Allergy Issues Alliance, and many of these are
4 specialized food trade associations that are
5 focused on various sectors of the food industry,
6 and we are going to be going out to our members
7 collecting information from food companies both
8 large and small to get a sense of how many have now
9 begun to use the plain language labeling that was
10 advocated along with other things that were
11 advocated in the Food Allergen Labeling Guidelines.

12 DR. LEWIS: Felicia Satchell.

13 MS. SATCHELL: My name is Felicia Satchell
14 and I'm with FDA. My first question is to Ms.
15 Katic. You had indicated that the voluntary
16 program is currently being implemented, and I
17 understand from Regina's last response that you are
18 beginning to work with the industry. Is there any
19 plan for follow-up, say, six, eight, ten months
20 down the road to see if all of your members are
21 implementing this, if they are complying with the
22 program? How do you plan to track follow-up?

23 MS. KATIC: Well, as Regina just
24 mentioned, we are developing, in the process of
25 developing a survey that will give us a baseline of

1 awareness and use of the program now, and we plan
2 on reinstating that survey in the spring and then
3 obviously probably next fall to track the changes
4 in usage and awareness.

5 MS. SATCHELL: What type of incentive, if
6 any, for voluntary compliance? I mean I can
7 appreciate your doing a survey, but let's say that
8 you have manufacturers that for financial reasons
9 find it too costly to relabel, what are your plans
10 for addressing members that may not be following
11 the guidance?

12 MS. KATIC: Well, I think, first of all,
13 the incentive is that no manufacturer wants to harm
14 any consumer, first and foremost. They take this
15 very seriously. Secondly, there are legal
16 issues that certainly no company wants to, you
17 know, have an issue with again harming a consumer.
18 So this is something that the industry has been
19 working on for decades, for a long, long time.
20 This is nothing new. This is something that the
21 industry continues to look at and refine and
22 redevelop.

23 So, you know, as I said in my comment,
24 this is something that has gotten to the highest
25 levels within our member companies. It's been

1 presented to our board of CEOs. Our CEOs are on
2 board and have given their support obviously and
3 encouragement for use of the program.

4 And I think through the survey, you know,
5 we're really going to have some understanding of--
6 the trade associations within the Alliance will
7 have some understanding of how it's being used and
8 obviously if it's not, then that will modify or
9 adjust our education and outreach efforts.

10 MS. SATCHELL: Thank you.

11 DR. LEWIS: Other questions? Dr. Falci.

12 DR. FALCI: This is Dr. Falci of the Food
13 and Drug Administration. I think there is a lot of
14 agreement that we have here and I'm pleased with
15 that. I'm trying to turn my head around so I can
16 see your format of ingredients that you have there,
17 Dr. Jacobson. And I think that's a very
18 interesting idea about having different kind of
19 formats for ingredients in the ingredient
20 statement.

21 But my question has to do a little bit
22 with consumer education. Maybe you could think
23 about that as I continue on here. That is consumer
24 education as far as the formats are concerned. One
25 of the things that I've seen is that there's a

1 large percentage of the population that are
2 unfortunately not interested in food allergens
3 because they don't have that problem, they don't
4 have to deal with it.

5 So when you sit down and you think about
6 trying to educate the consumer, it's hard to try to
7 think of maybe the appropriate way of approaching
8 people that might not be interested in it and to
9 try to get them more interested in that. So my
10 question again is how would you really begin to try
11 to educate the consumer?

12 I know that Lisa Katic had mentioned that
13 you're discussing that now. I'd be interested just
14 maybe if you could elaborate more on it, but some
15 of the things that came to my mind, of course, were
16 TV advertisements, of course, which are very
17 expensive, but maybe once you get into the school
18 programs about potential new formats as well. So
19 would anybody like to field that?

20 DR. JACOBSON: Well, I don't think we
21 could expect any kind of well-funded government
22 educational program that lasts for any significant
23 period of time. Measures should be self-actuating
24 and that's what a clear ingredient label is. It
25 makes it possible for consumers to actually read

1 the label as the law suggests.

2 Look at some of those products in front of
3 you. Tom, could you pass that thing over there?
4 These labels are designed not to be read. You'll
5 definitely need your glasses and a magnifying
6 glass, too.

7 [Applause.]

8 DR. JACOBSON: It's all upper case, skinny
9 little print, very small writing that may be
10 inevitable, but it goes--there are textbooks on how
11 to print things legibly. This violates every
12 precept in those textbooks, and if the information
13 is clear, it would make it a lot easier for
14 consumers to read the label whether it's for food
15 allergens or sugars or heart disease or
16 hydrogenated fat or whatever people are concerned
17 about.

18 DR. FALCI: Just as a follow-up to that, I
19 think one of the reasons why such a package is
20 created like that is unfortunately there is not a
21 lot of food in the particular containers, not
22 enough space on the container to have a large
23 letters, but I don't know how you'd overcome that.

24 DR. JACOBSON: Well, I think there's
25 certainly a variety of products. We found very

1 small print on very large packages also. But even
2 an example like that one before you, upper and
3 lower case printing would be a lot easier to read.
4 You know designers can make labels that are easier
5 to read or harder to read. Unfortunately, many
6 companies are choosing the latter.

7 DR. LEWIS: One more brief comment before
8 we move on.

9 MS. MUNOZ-FURLONG: In response to Dr.
10 Falci's question about how to educate the
11 consumers, if we're talking strictly about the
12 simple language labeling, they are already reading
13 labels, those that are affected, the food allergic
14 population. The problem is they can't understand
15 what they're reading. What we need to do is
16 simplify the labels so that when the children and
17 the adults and the teachers and so forth read them,
18 they'll understand what they're reading, and also
19 when that doctor makes a diagnosis and tells that
20 patient to read the label, they will then be able
21 to read it.

22 So in this issue I don't think it's such a
23 concern for education as it will be in some of the
24 other panels.

25 DR. LEWIS: We'll take one more brief

1 question from Felicia Satchell and then we'll move
2 to the cards.

3 MS. SATCHELL: The question is directed to
4 Dr. Jacobson and Ms. Munoz-Furlong. Both Ms.
5 Hildwine and Katic mentioned three or four options
6 in their presentation for presenting plain English
7 labeling in conjunction with the ingredient
8 statement. Allowing the flexibilities of these
9 options, do you see that as being a stumbling block
10 or confusing for allergic consumers?

11 MS. MUNOZ-FURLONG: On this issue, I don't
12 think that it will be. The fact is that they
13 reading the label. They need to have a place or a
14 statement that they can understand. If we're
15 looking at what they like, and I'll cover some of
16 that in the next panel, they would prefer that we
17 have a statement of "contains milk and eggs"
18 immediately after that ingredient statement because
19 then it saves them time. They don't have to read
20 that entire paragraph in very small print. They
21 can zoom in on that and put the package back on the
22 shelf if it's not safe for them or put it in their
23 shopping cart.

24 DR. LEWIS: Thank you very much.

25 DR. JACOBSON: I think there should be a

1 standardized label so consumers don't have to hunt
2 around and say, oh, is there an asterisk here or is
3 it boldfaced. It should always be in the same
4 place and as Ms. Munoz-Furlong suggested, something
5 at the end where it would say allergy information,
6 and then milk, soy, whatever, is the best option.

7 DR. LEWIS: Thank you to the panelists.
8 We'll now move to the questions from the audience,
9 and I have several here that I think will probably
10 easily take up our remaining time.

11 This question is about placement and it's
12 directed to either Ms. Katic and/or Ms. Hildwine.
13 Does the Alliance Allergy Labeling Program address
14 labeling ingredients above and below the package
15 seam?

16 For example, a Trail Energy Bar sent our
17 son to the hospital because we were unaware that
18 almonds were listed under the foil seam.

19 MS. HILDWINE: Well, that's a very
20 difficult situation, and a consumer shouldn't be in
21 that situation. Certainly, there are situations
22 with respect to the design of packaging that are a
23 challenge for the food industry.

24 The food companies do try to make that
25 information as clear as they possibly can given the

1 constraints of the package size. In fact, food
2 companies know that FDA has regulations regarding
3 the sufficient prominence of food label information
4 and, you know, NFPA does encourage its members to
5 follow those regulations all the time.

6 I think you'll see in some cases, though,
7 particular types of food are in particular types of
8 packages that make, you know, using all the label
9 space to present the required information very much
10 of a challenge and we are working with our members
11 to try and improve those situations.

12 MS. KATIC: The only thing I would add is
13 that the program that was developed by the Allergy
14 Issues Alliance does emphasize the prominence
15 within the ingredient panel declaration, and that's
16 what we would continue to support.

17 DR. LEWIS: Our second question from our
18 attendees seems to be addressed for anyone who
19 would like to deal with the topic. I suspect it's
20 more oriented towards industry.

21 The question is what about "contains milk,
22 wheat and egg ingredients," the way General Mills
23 and Kellogg's are labeling? Is this accepted to
24 the food allergic consumer? Is there data to
25 support the way the industry should go for consumer

1 clarity?

2 MS. HILDWINE: Well, I'll start with this
3 one as well. Certainly, those statements such as
4 "contains milk, wheat or egg ingredients," this is
5 one of the options that, in fact, the Food Allergy
6 Issues Alliance included in our Food
7 Allergen Labeling Guidelines. It is the top ranked
8 option, as a matter of fact, in our presentation of
9 the various options for presentation. And you know
10 we think that a lot of food companies are starting
11 to move in that direction to include this type of
12 information that specifically says at the end of
13 the ingredient statement that the product contains
14 these ingredients. It reinforces the information
15 in the ingredient statement.

16 MS. MUNOZ-FURLONG: Well, from the
17 consumer's perspective, General Mills and Kellogg's
18 are one of the companies that everybody talks
19 about. They like their labels. They're in simple
20 English and "that contains," and then the allergens
21 in simple language is perceived as a shortcut and a
22 very handy way to teach someone else how to read
23 that label.

24 DR. LEWIS: Anything else from our
25 panelist on this topic? We have a question to

1 three of the panelists regarding Dr. Jacobson's
2 presentation, and it has to do with his small board
3 that he presented. Do you folks support CSPI's
4 ingredient facts proposal? Can you discuss it?
5 Why and why not?

6 MS. MUNOZ-FURLONG: I can tell you that
7 the allergy information statement, we have
8 conducted some focus groups and people do like
9 allergy information. It could also be substituted
10 with "contain" statement and that would be
11 acceptable as well.

12 MS. HILDWINE: Just focusing on the
13 allergy information portion of the format for the
14 moment, certainly that does present one of the
15 options outlined in the food allergen labeling
16 guidelines. I think there are things, though, in
17 the format overall that need to be taken into
18 careful consideration.

19 A couple weeks ago when Dr. Jacobson
20 announced this new format, there was a side by side
21 comparison of a current ingredient list and the
22 proposed new format, and I, you know, just a minute
23 ago talked about the challenges of fitting required
24 label information on small packages, and if you do
25 that side by side comparison, you will see that the

1 proposed new format takes up a great deal of label
2 space. So that's a real practical problem that
3 certainly needs to be explored further.

4 DR. LEWIS: My remaining cards focus
5 largely on the issue of voluntary versus mandatory
6 labeling. In our remaining five minutes, I'll try
7 to summarize some of those. They are quite
8 overlapping.

9 There is a question for Ms. Hildwine. Is
10 your reason for supporting voluntary labels instead
11 of mandatory ones that it's too confusing for
12 manufacturers and the FDA to agree on this, and
13 therefore it would delay implementation? And if
14 so, why not implement voluntary rules now and work
15 on standard regulations for all companies?

16 MS. HILDWINE: Well, first of all,
17 voluntary rules is an oxymoron. There is really no
18 such thing. And certainly the work that the Food
19 Allergy Issues Alliance has been doing is a
20 voluntary approach and we announced this this
21 spring, and food companies, some had already been
22 following the precepts outlined in those
23 guidelines. Other companies are starting to do
24 that now.

25 We've been encouraging members to adopt

1 these presentation options and these guidelines.
2 Our concern is is that some food companies may say,
3 well, if FDA is going to develop regulations to
4 require this to adopt a mandatory approach, well, I
5 think maybe I'll just wait to see what the agency
6 does now.

7 In plain fact, going the mandatory route
8 will delay the adoption by the industry of those
9 presentation options that have been outlined in the
10 Food Allergen Labeling Guidelines. So we would,
11 you know, not just to mention the overwhelming
12 complexity of this--you may not realize it, but
13 when FDA, well, when the law changed to require
14 declaration of ingredients of standardized foods as
15 part of the Nutrition Labeling and Education Act,
16 FDA had to open up the regulations on every one of
17 the standards of identity.

18 I believe there are about 72 regulations
19 governing cheese, and this is only one category of
20 standardized food. FDA would have to make
21 amendments to an overwhelming number of
22 regulations. It's not just a simple matter of
23 requiring this in a particular section of
24 regulations.

25 So it would be very complicated. It would

1 take quite a long time. There is no reason to
2 wait. The voluntary program that's been
3 established by the Food Allergen Labeling
4 Guidelines is in implementation now. So we don't
5 think that anybody should wait for rules and that
6 it should continue to be on a voluntary basis.

7 DR. LEWIS: Thank you. Lisa.

8 MS. KATIC: Well, just building one
9 comment on top of that, I think Regina pretty well
10 laid out the complexity, which then leads to the
11 next point, why we think voluntary versus mandatory
12 is the way to go is that down the road the industry
13 sees this program as evolving.

14 If there is research, enough research that
15 is done on a particular ingredient that it does
16 prove that it becomes an allergen or is a problem
17 for the public, that would be incorporated into the
18 program and can be done right away, whereas waiting
19 for regulations to, you know, move through the
20 process could take one to two years, where as the
21 industry can act very quickly and institute or
22 implement something pretty quickly.

23 DR. LEWIS: My remaining cards really do
24 play on this, and you may have already made your
25 points, but I will offer these questions to you.

1 To Regina Hildwine, because recalls are so high, on
2 what basis do you think voluntary guidelines will
3 be enough, and is it enforceable?

4 To Anne Munoz, Furlong, does FAAN support
5 mandatory labeling and legislation in this area?

6 And then finally, if a number of NFPA and
7 GMA members already are labeling voluntarily or
8 plan to, why is the industry opposed to FDA
9 regulations which would reach all industry members
10 since those already doing this voluntarily will
11 just be ahead?

12 Again, those are issues you've been
13 addressing so I'll allow you to answer those or
14 build on other comments you've already made if you
15 wish.

16 MS. HILDWINE: Just with respect to the
17 issue of recalls, these, as I've observed them over
18 the past several years, are very much related to
19 undeclared allergens, outright undeclared
20 allergens. The issue of plain language labeling is
21 not question.

22 Also, oftentimes the presence, the
23 notation of a recall is an indication that
24 enforcement type activity may have begun with
25 respect to FDA. We believe that FDA has plenty of

1 authority to enforce regulations relative to
2 undeclared, any undeclared ingredient including
3 food allergens. That's all I have to say for that
4 one.

5 DR. LEWIS: Anne, did you want to make a
6 comment?

7 MS. MUNOZ-FURLONG: Yes. Regarding
8 whether FAAN is for or against or whatever the term
9 was for mandatory versus voluntary. FAAN's
10 position is that we know we need label improvements
11 immediately. We are going to support any and all
12 initiatives that are going to get us there be they
13 voluntary, regulatory, legislative, because
14 ultimately they're going to benefit the consumer.

15 [Applause.]

16 DR. LEWIS: In the last few minutes, does
17 anyone else on the panel have one more comment or
18 question before we take a break? Thank you. We
19 will take a 15 minute break, which means we'll be
20 back here just a little before 9:40.

21 [Whereupon, a short break was taken.]

22 DR. LEWIS: All right. Let's get started.
23 We do have a special presentation. I have been
24 asked to remind the audience to please make note of
25 the fact that there is no eating in the auditorium.

1 That's a very important issue here. Please do not
2 consume vitals here in this particular auditorium.

3 Our second panel addresses advisory
4 labeling, and before we actually get to the panel
5 presentations, we have with us today Ms. Theresa
6 Dziuk. She is with our Minnesota District at the
7 Food and Drug Administration, and she will be
8 presenting a summary of inspectional findings.

9 If you would please welcome, Ms. Dziuk.
10 Thank you.

11 [Applause.]

12 MS. DZIUK: I'd like to thank the center
13 for inviting me. I feel very fortunate to be here
14 today. When this started, I was a compliance
15 officer with the state of Minnesota. In 2000, I
16 joined the FDA as a consumer safety officer. In
17 October of 1998, the Food and Drug Administration
18 formed a partnership with both the Minnesota and
19 Wisconsin Departments of Agriculture.

20 This partnership was in response to
21 reports of consumers who experienced adverse
22 reactions following exposure to allergic substances
23 in foods which were not declared on the food label.
24 In addition, there was an increase in the number of
25 allergen related recalls, and we had concerns over

1 manufacturing controls of undeclared allergen
2 residues.

3 The goal of our partnership was to
4 eliminate duplicate inspections and sample
5 collections, to ensure uniform enforcement and to
6 obtain current information on allergy awareness and
7 provide feedback to industry.

8 While it is generally believed that nearly
9 every food can cause an adverse reaction, eight
10 foods are known to cause 90 percent. FDA
11 recognizes these as peanuts, soybean, milk and milk
12 products, eggs, wheat, tree nuts, fish and
13 crustacea.

14 Although this partnership looked at the
15 control of food allergens, we focused on industries
16 that used peanuts and eggs. Ice cream, bakery and
17 candy manufacturers were selected for coverage. 86
18 inspections were planned and 85 inspections were
19 conducted. Establishments inspected were 45
20 bakeries, 13 ice cream manufacturers, and 18 candy
21 manufacturers.

22 Inspections performed were routine GMP
23 inspections. That's good manufacturing practice
24 inspections. State inspectors and FDA
25 investigators were trained in August of 1999. To

1 ensure uniform application of current good
2 manufacturing practices, inspectors and
3 investigators were standardized during initial
4 joint inspections.

5 Inspections were conducted in September
6 '99 through March 2000. This was a small study.
7 Establishment selection was not intended to be
8 scientifically significant, but to provide an
9 overview of current industry practices. Selection
10 was made randomly of small, medium and large
11 establishments that were licensed and inspected by
12 the state departments of agricultures, that
13 conducted interstate commerce, and that were
14 jointly scheduled on the agency's workplans.

15 One measurement of establishment size used
16 by FDA is annual gross sales. What you'll see here
17 on the left side, there are nine categories of
18 annual gross sales. We broke those down into three
19 groupings and considered them small, medium and
20 large. I've broken out on the slides both
21 Minnesota and Wisconsin. We inspected 85 total
22 establishments. 17 were small, 51 medium, and 17
23 large.

24 During our inspections, our investigators
25 utilized a specialized questionnaire to aid in

1 assessing industry practices. Example of the areas
2 investigators observed during the inspections were
3 the use of shared equipment, production practices
4 such as handling of rework, labeling and product
5 changeover, and any other mechanism that related to
6 the control of allergens. Samples were obtained
7 based on observation.

8 This following series of slides has a lot
9 of information that I will not be covering. I'm
10 going to be presenting totals, and it's important
11 to recognize that there weren't differences between
12 Minnesota and Wisconsin.

13 Each of these graphs is broken down on the
14 left side by total, and then they're also broken
15 down by commodity. There are bakeries, ice cream
16 and chocolate. And again, I'm only going to be
17 focusing on the total, and I present this other
18 information so that you can see from your own
19 interest.

20 The product label is the primary means to
21 inform a consumer of potential product allergens.
22 Our questionnaire contained a section on the use of
23 allergenic ingredients. Ingredients used in the
24 formulation of the product were compared to the
25 corresponding finished product labeling.

1 45 of the 85 firms inspected, and that's
2 the blue bar right here, felt that they had
3 adequate procedures in place to verify label
4 accuracy. Of the 45 firms that felt that they had
5 adequate procedures to verify label accuracy, our
6 investigators found that 15 percent had incorrect
7 finished product labels.

8 Of the firms that didn't have procedures
9 to verify their labels, 51 percent had incorrect
10 finished product labels. Only one of the 85 firms
11 inspected had a policy against the use of advisory
12 labeling.

13 One bakery inspected reported that they
14 had received a consumer complaint. The consumer
15 stated that they had an allergic reaction after
16 consuming a product that normally would not contain
17 peanuts. The consumer called the bakery and said
18 they were allergic to peanuts and had the reaction
19 when they consumed this product. The bakery
20 reported to inform the consumer that the labels
21 states it may contain peanuts. The customer
22 appeared to be satisfied and had no additional
23 contact with the firm.

24 This is an example where advisory labeling
25 may not always be effective. An advisory labeling

1 statement such as "may contain" are not a
2 substitute for good manufacturing practices.

3 37 of the 85 firms inspected utilized
4 rework. Procedures for handling rework varied by
5 industry. Of the firms that utilized rework, 48
6 percent had product that tested positive for
7 undeclared allergen residues. When using shared
8 equipment, product changeover presents an
9 unintentional opportunity for product that contains
10 an allergen to contaminate a product that does not
11 contain an allergen.

12 Equipment cleaning is critical to the
13 control of allergens. While only three
14 establishments inspected utilized analytical test
15 methods to verify their cleaning and sanitization
16 procedures, 41 of the 85 had standard operating
17 procedures in place to control cross contact.

18 During our inspections, we observed that
19 production was frequently not scheduled.
20 Scheduling was conducted first in/first out where
21 the first order received would be the first order
22 manufactured, and allergen considerations were not
23 addressed.

24 Scheduling was based on the color of
25 production. For example, a sugar cookie would be

1 the first product manufactured, followed by various
2 flavored chips, then peanut butter cookies and then
3 finally ending the production run with gingersnaps.

4 Many firms did not have dedicated
5 equipment for allergen and non-allergen product
6 lines. Non-dedicated product lines were observed
7 to be inadequately cleaned between production.
8 Many times equipment was rinsed with only water or
9 the equipment was cleaned at the end of the day.
10 Only three of the 85 firms inspected utilized
11 personnel that were trained and dedicated to
12 allergen control.

13 At this time, a tolerance for undeclared
14 allergen residues has not been defined. A standard
15 method has not been approved by the AOAC. For the
16 partnership, we utilized an ELISA test kit that was
17 developed by the University of Nebraska and
18 manufactured by the Neogen Corporation. This was
19 used strictly as a screening tool.

20 Each sample was a composite of ten
21 eight-ounce subs and a ten part per million test
22 kit standard and a reagent blank were used as our
23 controls. We determined a sample positive if it
24 was reported positive at or above ten parts per
25 million.

1 Samples were not obtained at every
2 manufacturer inspected. Sample selection was based
3 on manufacturing practices observed during the
4 inspection. Our samples were used to confirm our
5 observational findings. A sample was obtained if
6 equipment was shared and a non-allergen containing
7 product was produced after an allergen containing
8 product without the equipment first being cleaned.

9 We identified areas where there was a
10 potential for cross contact and then took a sample.
11 Our goal was to assist industry in defining
12 critical control points in their process.

13 We collected 118 partnership samples for
14 analysis which was performed by the state
15 laboratories. 73 samples were obtained for
16 undeclared peanuts and 45 samples were obtained for
17 undeclared eggs. 73 of the 85 firms used peanuts
18 in their production. 18 of the 73 samples obtained
19 were found positive for undeclared peanut residues.
20 It's important to remember that we chose these
21 samples based on our observational findings. So we
22 expected to find residues in these samples, and
23 these 18 samples is equivalent to 25 percent of the
24 samples obtained.

25 When we look at the total picture

1 comparing our observations with the sample
2 analysis, it was observed that 49 percent of the
3 firms had a potential for cross-contact of
4 allergens into non-allergen containing products.
5 Of these firms, 50 percent had positive samples for
6 undeclared allergens. Of the firms that utilized
7 rework, 48 percent had samples that tested positive
8 for undeclared allergens. Of the firms that didn't
9 have procedures for label verification, 51 percent
10 had incorrect finished product labels.

11 Allergen awareness was very high in some
12 firms and extremely low in others. We held
13 industry workshops to provide feedback on our
14 partnership. Three workshops were held in May of
15 2000. We prepared an information pack with
16 allergen education materials and for the firms that
17 were unable to attend, we mailed this pack to them.

18 We conducted follow-up. All
19 establishments that were inspected received a copy
20 of their establishment inspection report. They
21 also received a copy of their analytical results.
22 We either met or sent a letter to the firms that
23 had samples which tested positive for undeclared
24 allergens and explained the significance of these
25 findings. We conducted follow-up inspections at

1 these firms during August of 2000.

2 We conducted 21 follow-up inspections and
3 collected 18 samples. We found that industry made
4 every effort to address and modify their good
5 manufacturing practices. The greatest change noted
6 was in addressing cross-contact in the form of
7 scheduling and sequencing. Firms dedicated
8 equipment to non-allergen and allergen-containing
9 products. They reconsidered their use of rework.

10 Many firms corrected their labels.
11 Sanitation practices were improved and verification
12 testing of equipment and finished product was
13 implemented. Many firms trained their employees on
14 the significance of allergen control.

15 Through this partnership, we felt that the
16 FDA and states gained credibility with industry.
17 We found that the industry was very open and
18 willing to share their manufacturing practices.
19 Adherence to good manufacturing practices are
20 essential in the reduction of undeclared allergen,
21 and advisory labeling is not a replacement for good
22 manufacturing practices.

23 We are all in this together as consumers
24 and labeling should be addressed as a food safety
25 concern. Thank you.

1 [Applause.]

2 DR. LEWIS: We'll now begin Panel II which
3 addresses the topic of advisory labeling. We have
4 four presenters. First, Ms. Lisa Katic. Second,
5 Regina Hildwine. Third, Anne Munoz-Furlong. And
6 last, Dr. Michael Jacobson. Lisa.

7 MS. KATIC: Thank you.

8 MS. KATIC: GMA supports the use of
9 supplemental statements such as "may contain
10 peanuts" consistent with the criteria established
11 in the Food Allergen Labeling Guidelines prepared
12 by the Allergy Issues Alliance. These guidelines
13 clearly state that consistent with the FDA policy
14 on this issue, supplemental allergen statements
15 should not and cannot be used in lieu of good
16 manufacturing practices.

17 In addition, the guidelines restrict the
18 instances in which a manufacturer can use these
19 kinds of statements. Under the guidelines,
20 supplemental statements only can be used when:

21 (1) The presence of a major food allergen
22 is documented through visual examination or
23 analytical testing of the processing line,
24 equipment, ingredient or product or other means;

25 (2) The risk of a presence of a major food

1 allergen is unavoidable even when current good
2 manufacturing practices are followed;

3 (3) A major food allergen is present in
4 some but not all of the product; and

5 Last, the presence of a major food
6 allergen is potentially hazard.

7 If some but not all of these four criteria
8 are met, the guidelines do not allow the
9 manufacturer to use a supplemental allergen
10 statement. In such instances, the manufacturer
11 must either consider an additional food allergen
12 control measure and/or some other labeling
13 strategy.

14 With regard to the placement of the
15 supplemental allergen statement, the guidelines
16 require the statement to appear at the end of or in
17 immediate proximity to the ingredient statement.
18 The guidelines require that the statement be as
19 accurate and as conspicuous as possible. Examples
20 of the type of supplemental statements that are
21 being used include "may contain peanuts" and
22 "processed on the same equipment as milk."

23 The guidelines provide the manufacturer
24 with the flexibility to determine the type of
25 supplemental statement that will best describe the

1 product.

2 Supplemental allergen statements are an
3 integral component of the Alliance's labeling
4 document. Although the food industry is diligent
5 in its efforts to prevent major food allergens from
6 inadvertently ending up in food products, the
7 nature of the food supply and our manufacturing
8 processes in some instances make it impossible to
9 avoid.

10 Farmers generally grow numerous crops and
11 use the same equipment to harvest, store and
12 transport corn, soybeans, wheat, peanuts and other
13 crops. This can lead, for example, to the presence
14 of soy in corn or wheat in peanuts.

15 Inadvertent contact can also occur in the
16 manufacturing facility where the same processing
17 equipment is used to manufacture a wide variety of
18 products. In an attempt to prevent the inadvertent
19 presence of allergens in products, many in the food
20 industry have adopted a three-tiered approach to
21 minimize this inadvertent contact with allergens.

22 This approach involves dedication when
23 possible, separation, and as a last resort
24 labeling. First, when possible, the industry will
25 use a dedicated system. This may be possible for

1 some large volume products where continual
2 production on the same or multiple lines is needed
3 to meet consumer demand. It is not financially
4 possible, however, to have a dedicated system for
5 each product that is manufactured by a company.

6 When a dedicated system is not a
7 possibility, the company will use separation as a
8 means to minimize inadvertent contact. This can be
9 accomplished by physical barriers, the use of
10 dedicated containers for raw materials that contain
11 allergens, and other means to prevent the
12 inadvertent contact of a major allergen with
13 non-allergenic ingredients.

14 Companies will also schedule production so
15 that when possible, a non-allergen containing
16 product will be manufactured on a line before a
17 product that contains an allergen.

18 Companies will also thoroughly clean a
19 line that has been used to manufacture a product
20 containing a major food allergen before
21 manufacturing a product that does not contain that
22 allergen.

23 Cleaning, however, will not always succeed
24 in removing the allergens from all services of the
25 equipment. It has been proven time and time again

1 that water is the most efficient method for
2 removing allergenic proteins from processing
3 equipment. There are numerous foods and food
4 systems, however, where water cannot be used as
5 part of the cleaning process due to the nature of
6 the food or due to microbiological safety concerns.

7 Chocolate and peanut butter manufacturing
8 systems are examples of processes where water
9 cannot be used to clean the machinery because these
10 foods do not readily dissolve in water and the use
11 of water can lead to microbiological concerns due
12 to the puddling of water somewhere in the system.

13 Water also cannot be used in the cleaning
14 of certain packaging and electrical equipment such
15 as baking ovens and cooling tunnels for obvious
16 reasons. Water and electricity don't match.

17 In instances when water cannot be used for
18 cleaning, the food industry frequently will use a
19 dry process for cleaning, such as flushing the line
20 with a safe, non-allergenic dry ingredient or food
21 that removes the food from the system.

22 The use of these dry ingredients is
23 recognized as an appropriate good manufacturing
24 practice and in many instances is dictated by the
25 microbiological concerns that are present by wet

1 cleaning.

2 The use of dry ingredients to clean a
3 system, however, is not always successful in
4 completely and 100 percent removal of the
5 allergens. Systems that rely on this type of
6 cleaning frequently cannot be cleaned to remove all
7 residues of a major allergen.

8 In those instances when neither dedication
9 nor separation can prevent the inadvertent contact
10 with the major allergen, the industry will resort
11 to labeling, labeling consistent with the four
12 criteria established in the Alliance's labeling
13 program that I stated earlier.

14 These criteria are designed to ensure that
15 supplemental allergen statements are used only in
16 limited situations and not as a substitute for good
17 GMPs.

18 Supplemental allergen statements are
19 designed to alert the food allergic consumer that
20 the product in question may have an allergen that
21 they need to avoid. We recognize that a certain
22 percentage of a given product bearing this
23 supplemental allergen statement may be free of the
24 named allergen and safe for consumption for the
25 food allergic consumer. However, the allergen may

1 be present in some of the foods manufactured on
2 that line. Thus, necessitating the use of a
3 supplemental statement that alerts the food
4 allergic consumer to the possible presence of this
5 allergen.

6 As stated in many comments earlier, we
7 believe that the allergen labeling issues can be
8 best addressed through the voluntary program and
9 that additional regulations are unnecessary.
10 Although the existing regulations do not mandate
11 the use of common English names or establish
12 criteria for the use of supplemental allergen
13 statements, the industry through the Alliance has
14 reached agreement on these labeling issues and is
15 now in the implementation phase.

16 We believe that continued educational
17 efforts will be one of the most effective means to
18 address this issue. GMA has educated its member
19 companies about the importance of the allergen
20 issue, and as stated this morning, the senior
21 management from each of our member companies has
22 agreed to adopt the labeling program.

23 We recognize, however, that we also have
24 to reach the small and medium sized companies that
25 may not be members of GMA or of the other alliances

1 that are part of the Allergy Issues Alliance. The
2 Allergy Issues Alliance is in the process of
3 developing educational programs for these other
4 smaller companies. Moreover, FDA has the existing
5 statutory and regulatory tools to take enforcement
6 action against those companies that market products
7 with undeclared allergens.

8 The unacceptably high level of recalls due
9 to the presence of undeclared allergens is perhaps
10 the strongest evidence supporting the agency's
11 ability under its existing regulatory framework to
12 address this issue.

13 We also encourage FDA to develop and
14 maintain a strong enforcement presence for food
15 allergens. One of the best ways to effect change
16 and to encourage all companies regardless of size
17 to make certain that their products are properly
18 labeled and that their foods are manufactured in
19 accordance with good GMPs is through continued
20 inspections and when necessary enforcement actions.

21 We believe that a strong FDA presence and
22 the knowledge that there is a "cop on the beat," if
23 you will, would be a much more effective use of
24 agency resources rather than additional
25 regulations.

1 In conclusion, GMA supports the use of
2 supplemental allergen statements in those limited
3 instances when the four criteria in the Alliance's
4 labeling program are satisfied. Consistent with
5 FDA's guidance on this issue and the terms of the
6 Alliance's labeling program, supplemental allergen
7 labeling cannot and should not be used as a
8 substitute for GMPs. Thank you.

9 [Applause.]

10 MS. HILDWINE: Thank you very much.
11 Episodes of inadvertent cross-contact between foods
12 that contain major allergens and foods that are not
13 intended to contain those allergens coupled with
14 the resultant problem of undeclared allergens in
15 the product where they are not intended indicate
16 that both production controls and labeling
17 approaches must be discussed for these foods.

18 FDA's questions focus on the issue of
19 supplementary or advisory labeling, the so-called
20 "may contain" statements. But NFPA believes that
21 this discussion may include a mention of
22 manufacturing practices. NFPA believes that this
23 is the correct approach since we advocate the
24 limited and carefully controlled use of
25 supplementary of advisory food allergen labeling.

1 Food processors that prepare foods that
2 may be exposed to inadvertent contact with major
3 food allergens acknowledge that labeling is not a
4 substitute for good manufacturing practices. GMPs
5 and their resultant controls must be considered
6 first before labeling approaches are considered.
7 Processors should review the plant environment
8 including storage conditions and production line
9 architecture; should review the products, controls
10 and practices of their supplier; should examine
11 their own production operations, including
12 separation, sanitation and scheduling practices;
13 and then should create optimum conditions for food
14 allergen control including employee training as far
15 as they are able.

16 When this process is completed, if the
17 risk that the food allergens may be present, that
18 risk still exists, then supplementary allergen
19 labeling must be considered. Supplementary or
20 advisory labeling should not be an easy shortcut to
21 bypass activities that are food processors'
22 responsibilities, but rather should be viewed as an
23 approach of last resort when the risk of presence
24 of a food allergen cannot be avoided with absolute
25 certainty.

1 Supplementary or advisory labels should be
2 relatively rare, not increasingly more common.
3 Nevertheless, given the difficulties of achieving
4 absolute certainty that there is no risk of
5 presence of major food allergens in a variety of
6 operational situations, supplementary or advisory
7 labeling is necessary and should be permitted.

8 The food industry has taken numerous steps
9 over the past several years to change manufacturing
10 processes to reduce the potential for cross-contact
11 with major food allergens. At NFPA, we have a Food
12 Allergens Committee that has been working, meeting
13 for several years, to discuss these practices. As
14 a result of these discussions, last year NFPA
15 issued a "Code of Practice for Controlling Food
16 Allergens," and this year we have started an
17 elaboration of the Code of Practice, a how to
18 implement the code of practice for the use of our
19 members, which, by the way, cover the broad gamut
20 of food processing, various sectors in the food
21 processing industry.

22 The food industry recognizes that under
23 existing GMP regulations, reasonable precautions
24 must be taken to prevent cross-contact with major
25 allergenic proteins. In instances, when

1 cross-contact cannot be avoided even when complying
2 with GMPs, food and ingredient manufacturers then
3 use labeling that informs the food allergic
4 consumer of the possible presence of allergens in
5 the food.

6 However, only supplementary label
7 statements that are used in careful controlled
8 circumstances would provide a food allergic
9 consumer with enough information to make a clear
10 decision about whether or not a food is appropriate
11 for them to eat.

12 The Food Allergen Labeling Guidelines of
13 the Food Allergy Issues Alliance outlined four
14 conditions that spell out the carefully controlled
15 circumstances to govern responsible consideration
16 of supplemental food allergen statements. Lisa
17 went through these and I'm going to do it again
18 because we believe these are very important.

19 The guidelines present a reasonable yet
20 rigorous approach to the criteria for determining
21 whether supplemental labeling statements should be
22 used. These type of food allergen statements
23 should be used judiciously only when all four of
24 the following criteria are met:

25 First, the presence of a major food

1 allergen is documented through visual examination
2 or analytic testing of the processing line,
3 equipment, ingredient or product, or through other
4 means.

5 Thus, the first step is to affirm that the
6 major food allergen is in the environment. This
7 affirmation can be accomplished through examination
8 of the physical plant, processing procedure,
9 analytical testing where available, or through
10 documentation.

11 Second, the risk of presence of a major
12 food allergen is not unavoidable even when current
13 good manufacturing practices are followed. This
14 criterion signifies that all the feasible
15 operational issues that can be addressed have been
16 addressed with respect to control of the major food
17 allergens, yet even under those conditions, there
18 is not a complete certainty that one can avoid the
19 risk that the allergen could be present.

20 Third, the major food allergen is present
21 in some but not all of the product in question.
22 Clearly, if this criterion is not met, "may
23 contain" type label statements could not apply. If
24 the allergen is present in all of the product,
25 there is nothing may about it. The product does

1 contain the allergen.

2 The occasional or sporadic presence of an
3 allergen may provide additional information that
4 allows the food processor to diagnose a situation
5 with a supplier, the plant environment, a piece of
6 equipment or a processing procedure. This
7 information would then trigger a review back to the
8 second criterion.

9 If one can identify a feature that would
10 enable the processor to control further the risk of
11 presence of an allergen, then steps should be taken
12 to exert additional controls.

13 This third criterion highlights that the
14 review of allergen control procedures is not
15 static, but dynamic. Review of the criteria for
16 supplemental labeling should be undertaken whenever
17 there is a change to one of the operating variables
18 such as ingredients, suppliers, equipment or
19 processing techniques.

20 The fourth criterion is that the presence
21 of the major food allergen is potentially
22 hazardous. At the present time, scientists do not
23 agree that there is a condition under which the
24 presence of the major food allergen is not
25 potentially hazardous, so this particular criterion

1 at the present time would always apply.

2 Now, if some, but not all of these
3 criteria are met, food and ingredient manufacturers
4 should consider food allergen control or food
5 allergen labeling strategies other than
6 supplemental allergen statements. Meeting all four
7 criteria will ensure that supplementary or advisory
8 label statements are considered only after due
9 diligence.

10 Meeting all the criteria also ensures that
11 labeling statements are not used capriciously or as
12 a theoretical precaution. For food processors,
13 adhering to these criteria undoubtedly will have
14 associated costs for reviews, self-inspections,
15 audits, documentation of procedures,
16 post-sanitation testing, personnel training and
17 sometimes new equipment or facilities.

18 However, failure to be vigilant with GMPs
19 or such widespread use of supplemental labeling
20 that food allergic consumers no longer believe the
21 statements, these can have consequences that are
22 not only costly but are tragic.

23 If supplemental allergen labeling is used
24 responsibly, the likelihood is that food allergic
25 consumers will believe the statements and will

1 statement should be to prompt food allergic
2 consumers to draw the conclusion that they should
3 not consume the product.

4 In order to provide for different
5 production circumstances, there should be
6 flexibility to the presentation of supplementary or
7 advisory food allergen statements. If such
8 statements are to be accurate, then the
9 one-size-fits-all approach is not feasible.

10 For this reason, FDA should permit but
11 should not mandate such labeling in proximity to
12 the ingredient declaration and food processors
13 should adhere to the necessary food allergen
14 controls and evaluation criteria regarding the use
15 of these statements. Thank you.

16 [Applause.]

17 MS. MUNOZ-FURLONG: I have some slides.
18 Okay. What I'm going to talk about I will continue
19 to refer to as "may contain" labeling, but I really
20 am intending for it to be all of the precautionary
21 allergen statements.

22 May I have the next slide? Now my
23 objectives here are to provide you with information
24 about what the industry is currently doing and how
25 that is impacting on the consumer and the consumer

1 last week, and the product that their child has
2 been eating for years and years has been safe.
3 This week, they can no longer purchase that product
4 because it says main contain on it.

5 The only difference is that the "may
6 contain" has been added to the ingredient
7 declaration. There are no other ingredients that
8 have changed. This is causing a lot of frustration
9 and a lot of confusion to the allergic consumer.

10 Can we go back on that slide one more
11 time? We can't go back. Okay. All right. Well,
12 I'm going to make my point anyway. The point is
13 that because of the proliferation of "may contain"
14 statements, the integrity of all of the
15 precautionary labels are being questioned by
16 consumers.

17 A perfect example came to our office
18 several days ago. One of our members was on an
19 airplane and was given a bag of raisins. She
20 looked at the ingredient label simply because our
21 members are trained to read ingredients for
22 everything. On a bag of raisins, it said may
23 contain peanuts. You have to wonder what's going
24 on.

25 Now, as a result of the proliferation of

1 some of these statements, some of the physicians
2 are telling their patients to ignore these
3 statements because they're on everything and they
4 don't believe that they're really there for anybody
5 but the company's safety.

6 As a result, some patients are making the
7 decision on their own to ignore these statements.
8 This to me is playing Russian roulette. The other
9 concern I have about this is that we are talking
10 about children and it concerns me greatly that
11 parents and others are making decisions because
12 they're so confused about what's going on out
13 there.

14 Next slide, please. Now, as I mentioned
15 earlier, when we asked for the write-in to our
16 survey, what were the three major concerns from our
17 membership, "may contain" was at the top of the
18 list. Some of the comments that we got, and we got
19 hundreds of comments in our book about some of
20 these issues, were that "may contain" is perceived
21 to be a defensive legal tactic or a way of avoiding
22 good manufacturing practices.

23 Again, this is because the consumers have
24 been left to their own to try and decipher some of
25 these labels.

1 Now when we go on and look at some of the
2 data from our study, when we asked them how the
3 perceive these statements, if it says contains
4 whatever the allergen is, 96 percent of the
5 membership reported that they do not purchase that
6 product.

7 When they see "may contain," 92 percent do
8 not purchase that product. When they see
9 "processed on shared equipment," 87 percent of the
10 people do not purchase the product. And
11 manufactured in a plant that also produces nuts or
12 peanuts or whatever the allergen is, 66 percent
13 never purchase the product.

14 The point I want to make here is that if a
15 company is putting these types of statements,
16 manufactured in a plant or processed on shared
17 equipment, because of a risk to the consumer,
18 because they intend that the consumer not purchase
19 that product, we can see from this information that
20 they're missing the mark, and there is a huge group
21 of people that are at potential risk because they
22 don't understand what you're trying to tell them
23 with these labels.

24 Now when we drilled down a little deeper
25 and we asked about the "may contain," how do they

1 interpret this, "may contain" to this group is a
2 gray area. They live in a black and white world.
3 If you're allergic, you avoid the food. "May
4 contain," they ask is it in there or isn't it in
5 there, how can we tell?

6 When we asked about may contain any and
7 all of the following, and then there is usually a
8 long list of allergens, they want to know when is
9 it in there? How can we tell? Is there a code on
10 the package? How does this happen that a
11 manufacturer does not know what is in the product
12 that I'm about to eat? And then don't they clean?
13 They're concerned that these statements are being
14 used in lieu of good manufacturing practices.

15 Next slide, please. And when we ask them
16 about manufactured in a plant that also
17 processes--most commonly we see this with nuts or
18 peanuts, they questions that came back to us and
19 that are coming back to the industry, are how far
20 is the allergen and non-allergen containing
21 equipment from each other, and when you give me
22 that information, can you tell me what the risk
23 will be to me?

24 Obviously, none of us can answer this
25 question. Therefore, this kind of labeling raises

1 more questions to the consumer than it really
2 answers and it causes again additional frustration.
3 Another problem that we're seeing with this type of
4 labeling is when we have multiple product packages,
5 the outside of the product packaged does not match
6 what's inside so we may have a may contains
7 something on individual packages on the inside, but
8 not on the outside.

9 Next slide, please. Now when we asked
10 them about contains, and I mentioned this at the
11 earlier panel, this to them is very black and
12 white. It contains it. I'm allergic. I can't
13 have it.

14 If they see the allergens bolded or
15 highlighted or in a contains statement immediately
16 after the ingredient declaration so that it's still
17 within that visual range that they scan on that
18 package, this again is a shortcut and is perceived
19 to be a favor that a company is doing to them
20 because it's helping them read that label very
21 quickly and it saves time with each product that
22 has to be read.

23 So, in summary, the food allergic
24 consumers need to know what is in the product.
25 This is a health and safety issue for this

1 population. The companies have a responsibility to
2 provide accurate, reliable, consistent information
3 about that information, and I think we all agree
4 that we all need a standard guideline for when
5 these precautionary statements will be used so that
6 we can educate the consumer about what they are
7 supposed to do when they see these statements.

8 We also would like all companies to use
9 these statements judiciously. Now, the guidelines
10 that we worked with on the industry certainly
11 address this issue, and I applaud the companies
12 that worked on this with us and are already doing
13 this. However, I am concerned as I hear more and
14 more smaller companies saying we're not going to do
15 this until it's regulated and we will wait and see
16 what FDA does.

17 So there is a lot of work that needs to be
18 done in this issue. I'd also like to make a point
19 that this is an international issue. We are
20 hearing the same thing from our colleagues in other
21 countries.

22 If we could have the lights, I want to
23 read very quickly in my remaining two minutes an
24 e-mail that is very typical of what we get in our
25 office from our members. This is from a woman who

1 says my son has tree nut allergies. Recently it
2 seems that many manufacturers are placing warning
3 statements on their packages such as "may contain
4 nuts," "may contain traces of peanut or other nut
5 particles due to manufacturing," or a candy corn
6 product that the list includes "may contain
7 peanuts, walnuts, almonds, pecans, cashews and
8 other ingredients."

9 I realize that the foods might be
10 manufactured on the same machinery as foods that do
11 contain nuts, but it is increasingly difficult to
12 know the true ingredients. I'm afraid it will
13 become likened to the boy who cried wolf and we
14 will all start doubting the ingredients. And with
15 that, I'd like to conclude. Thank you.

16 [Applause.]

17 DR. LEWIS: Just a quick reminder to the
18 audience, you can write your questions on the cards
19 and we will have someone collect them from you.

20 DR. JACOBSON: Contamination of food with
21 undeclared allergens is what makes life so fearful
22 for people with severe allergies. They live in
23 terror that a food contains an allergen not listed
24 on the label.

25 Unfortunately, such contamination occurs

1 fairly frequently as we heard a few minutes ago
2 from the FDA consumer safety officer who did the
3 study in Minnesota and Wisconsin.

4 That study found that in a selected sample
5 of 85 ice cream cooking and candy manufacturers, 21
6 marketed products containing undeclared peanut or
7 egg ingredients, and those are the only two
8 allergens studied. If they had looked at others,
9 there may have been other problems.

10 Similarly, the Oregon Department of
11 Agriculture tested 62 chocolate candies that were
12 not supposed to contain peanuts, but 23 percent of
13 those did contain significant levels of peanuts,
14 and University of Nebraska researchers found peanut
15 allergens in four out of 19 packaged foods that
16 neither listed peanuts as an ingredient nor warned
17 consumers that the products might contain peanuts.

18 In some of those cases, the products may
19 simply have been mislabeled. Others may have been
20 unintentionally contaminated. Though actual
21 problems from cross-contamination are very
22 difficult to identify, at least three reports in
23 the medical literature have found
24 cross-contamination having caused allergic
25 reactions.

1 In two different cases, toddlers suffered
2 anaphylaxis due to milk protein in sorbets. Peanut
3 antigen in gingersnap cookies was the cause of a 34
4 year old man's reaction.

5 "May contain" language is sometimes
6 appropriate to inform consumers of the presence of
7 possible allergens. But excessive use of such
8 statements deprives sensitive consumers of choice
9 and may cover up sloppy manufacturing practices.

10 We strongly support the FDA's position
11 that quote "such labeling should not be the norm
12 and that manufacturers should strive to eliminate
13 the presence of allergenic materials that are not
14 intentionally added to a specific food product."

15 That policy was first enunciated in
16 Commissioner Kessler's 1996 letter to food trade
17 associations stating that quote: "Precautionary
18 labeling should not be used in lieu of strict
19 adherence to good manufacturing practice to
20 effectively reduce and eliminate the likelihood of
21 cross-contamination, label mix-up or employee
22 error." Five years ago.

23 Unfortunately, we have heard that some
24 industry lawyers are advising manufacturers not to
25 test for allergens because of product liability